DAMGO NEW
| Price | $43 | $55 | $79 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: DAMGO | CAS No.: 78123-71-4 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | DAMGO |
| Description | DAMGO (DAGO) is an opioid receptor agonist with the ability to affect the locomotive activity in rodents. Possible analgesic agent due to μ-opiod receptor interaction. |
| In vivo | (1) DAMGO inhibits GABAergic inputs in VTA-DA neurons at presynaptic sites; (2) effect of DAMGO on GABAergic inputs in VTA-DA neurons is inhibited by potassium channel blocker 4-aminopyridine (4-AP) and Gi protein inhibitor N-ethyl maleimide (NEM); (3) phospholipase A2 (PLA2) does not mediate the effect of DAMGO on GABAergic inputs in VTA-DA neurons, but mediates it in the periaqueductal gray (PAG); (4) multiple downstream signaling molecules of l receptors do not mediate the effect of DAMGO on GABAergic inputs in VTA-DA neurons. These results suggest that DAMGO depresses inhibitory synaptic transmission via l receptor-Gi protein-Kv channel pathway in VTA-DA neurons, but via l receptor-PLA2 pathway in PAG |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 10 mg/mL (19.47 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.89 mM), Sonication is recommended. DMSO : 145 mg/mL (282.33 mM), Sonication is recommended. |
| Keywords | μ-OPR | μ-opioid receptor | RX783006 | RX 783006 | OpioidReceptor | Opioid Receptor | DAMGO | analgesic effect |
| Inhibitors Related | Docusate sodium | Bevenopran | Mirtazapine | Matrine | (-)-Menthol | Cuminaldehyde | Progesterone | Naltrexone hydrochloride | Cebranopadol | BTRX-335140 | Bisacodyl | Mianserin hydrochloride |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Neurotransmitter Receptor Compound Library | Peptide Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00 |
Shanghai Chinqesen Biotechnology Co., Ltd.
|
2024-03-31 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY